GlassScriptPhysician profile
Charles C Schirmer
NPI 1376507855
$51,705.30
in general payments reported to CMS, 2019-2025
18 companies · $7,289 in 2025
The $7,289 reported for 2025 was more than what 99% of Chemical Pathology providers received nationally (typical 2025 total: $34.99).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,765 · 2020: $125 · 2021: $7,117 · 2022: $11K · 2023: $13K · 2024: $11K · 2025: $7,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Travel and Lodging: $516 · Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $26,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Travel and Lodging | $515.93 |
| Food and Beverage | $407.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $47,677.53 | 2021-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Astrazeneca Pharmaceuticals LP | $2,465.70 | 2019-2020 | |
| Beckman Coulter, INC. | $674.83 | 2023 | Dxh 900 Hematology System, Unicel Dxh 690t Coulter Cellular Analysis System |
| Menarini Silicon Biosystems, INC. | $165.36 | 2024 | |
| Abbott Laboratories | $130.84 | 2020-2025 | Alere Triage |
| Bayer Healthcare Pharmaceuticals INC. | $126.78 | 2019-2020 | |
| Lilly USA, LLC | $126.07 | 2019-2021 | |
| Celgene Corporation | $65.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.60 | 2019-2020 | |
| Seagen INC. | $46.67 | 2021-2022 | |
| Roche Diagnostics Corporation | $28.90 | 2022 | |
| Merck Sharp & Dohme LLC | $27.25 | 2019-2020 | |
| Daiichi Sankyo INC. | $22.76 | 2020 | |
| Eisai INC. | $22.19 | 2023 | |
| Servier Pharmaceuticals LLC | $21.45 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $20.69 | 2022 | |
| Abbvie INC. | $16.55 | 2025 | |
| Exelixis INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Schirmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.